IPL 576092

Drug Profile

IPL 576092

Alternative Names: 4011; HMR 4011A; IPL 576,092

Latest Information Update: 05 Jun 2007

Price : $50

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Allergic rhinitis; Asthma
  • Discontinued Atopic dermatitis; Ocular inflammation

Most Recent Events

  • 13 Jul 2004 No development reported - Preclinical for Ocular inflammation in Canada (Ophthalmic)
  • 13 Jul 2004 Phase-I clinical trials in Atopic dermatitis in Canada (Topical)
  • 26 Feb 2003 Preclinical trials in Atopic dermatitis in Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top